-
Published 3/10/2025
Radwan A, Jani CT, Al Omari O, Patel M, Burns L, Mackay Z, Li L, Mahdaviani K, Davidson A, Weinberg J, Everett PC, Suzuki K, Mak KS, Kulke MH, Tapan U. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. Oncologist. 2025 Mar 10; 30(3). PMID: 39603266.
-
Published 1/17/2025
Perez K, Kulke MH, Zheng H, Allen J, Clark J, Enzinger AC, Enzinger PC, Johnson BE, McCleary NJ, Parikh A, Patel A, Rubinson D, Yurgelun MB, Ramsey K, Johnson E, Graham C, Chan JA. A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors. Oncologist. 2025 Jan 17; 30(1). PMID: 39834129.
-
Published 9/16/2024
Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665. PMID: 39282913.
-
Published 9/5/2024
Lazzaro A, Zhao GQ, Kulke M. Diagnosis and Management of Parathyroid Carcinoma. Clin Pharmacol Ther. 2024 Dec; 116(6):1496-1505. PMID: 39234888.
-
Published 4/12/2024
Hernando J, Roca-Herrera M, García-Álvarez A, Raymond E, Ruszniewski P, Kulke MH, Grande E, Carbonero RG, Castellano D, Salazar R, Ibrahim T, Teule A, Alonso V, Fazio N, Valle JW, Tafuto S, Carmona A, Navarro V, Capdevila J. Corrigendum to "Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours" [Eur J Cancer 188 (2023) 39-48]. Eur J Cancer. 2024 May; 203:114061. PMID: 38609739.